Leqvio Mental Health and Mood Impact: What the Clinical Evidence Shows

What Is Inclisiran and Why Does Mental Health Come Up?

Inclisiran is a small-interfering RNA (siRNA) that targets PCSK9 messenger RNA inside hepatocytes, blocking production of the protein that degrades LDL receptors. Two injections per year sustain roughly 50% LDL-C reduction in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). The FDA approved it in December 2021 [1].

Mental health questions surface for a specific reason: cholesterol is a structural component of neuronal membranes and a precursor to steroid hormones, including those that regulate mood. When any agent lowers LDL-C dramatically, some patients and clinicians wonder whether that reduction could alter brain chemistry. That concern is not unfounded in principle, but the clinical trial data for inclisiran tell a reassuring story so far.

The Low-Cholesterol Mood Hypothesis

Early observational data from the 1990s suggested associations between very low total cholesterol and increased rates of depression and suicide. A 1992 meta-analysis in The Lancet raised that possibility, though methodological limitations were significant [2]. Subsequent prospective work has not consistently replicated a causal link, and statins, which reduce LDL by 30 to 55%, have been prescribed to hundreds of millions of people without a confirmed psychiatric safety signal across large randomized populations.

Inclisiran achieves comparable or slightly larger LDL reductions than high-intensity statins, so the same theoretical concern applies. The question clinicians should ask is whether the phase 3 trial data show any emergent psychiatric signal.

How PCSK9 Inhibition Differs Neurologically

Inclisiran does not cross the blood-brain barrier. Its siRNA payload acts exclusively in the liver. That pharmacokinetic reality means direct central nervous system exposure is not expected, which distinguishes it mechanistically from drugs that act on brain receptors. PCSK9 is expressed in the brain, but inclisiran's siRNA is taken up by hepatocytes via GalNAc conjugation and does not distribute meaningfully to neural tissue based on preclinical biodistribution studies [3].

ORION-10 and ORION-11: The Primary Safety Evidence

The two key phase 3 trials, ORION-10 (N=1,561) and ORION-11 (N=1,617), were published together in the New England Journal of Medicine in 2020 [4]. Both were randomized, double-blind, placebo-controlled trials of 18 months' duration. ORION-10 enrolled patients with ASCVD on maximally tolerated statin therapy in the United States; ORION-11 enrolled a broader international population including patients with ASCVD or high cardiovascular risk.

Primary Efficacy Results

In the pooled analysis, inclisiran reduced LDL-C by 49.9% from baseline at day 510 (P<0.001 vs. Placebo) [4]. That magnitude of reduction has been consistently maintained across the dosing intervals, confirming the twice-yearly regimen is pharmacodynamically durable.

Psychiatric and Neurological Adverse Event Reporting

The ORION-10 and ORION-11 publications reported adverse events by system organ class. Nervous system disorders occurred in 13.8% of inclisiran-treated patients versus 14.4% of placebo recipients in the pooled data, a difference that did not reach statistical significance [4]. Psychiatric disorders as a category appeared in fewer than 5% of participants in either arm, with no statistically significant between-group difference reported by the investigators.

Specific adverse event terms logged under psychiatric disorders included insomnia, depression, and anxiety. None showed a rate elevation in the inclisiran arm that the investigators flagged as a safety concern. The trial was not powered to detect rare psychiatric events, but the directionality of data does not suggest harm.

Neurocognitive Outcomes in ORION-1

The earlier ORION-1 phase 2 trial (N=501) specifically examined neurocognitive function as a secondary endpoint using the Cambridge Neuropsychological Test Automated Battery (CANTAB). Scores for spatial working memory, reaction time, and pattern recognition were compared between inclisiran and placebo groups at 180 days. No statistically significant differences emerged on any CANTAB subscale [5]. This is consistent with findings from evolocumab and alirocumab trials (FOURIER and ODYSSEY OUTCOMES), which also included formal neurocognitive testing and found no drug-related impairment [6, 7].

Comparing Inclisiran to Other PCSK9 Inhibitors on Mental Health

FOURIER (Evolocumab) Neurocognitive Data

The FOURIER trial (N=27,564) evaluated evolocumab on top of statin therapy over a median 2.2 years. A prespecified neurocognitive substudy (EBBINGHAUS, N=1,204) assessed cognitive function using spatial working memory, executive composite scores, and psychomotor speed. The EBBINGHAUS investigators reported no significant difference between evolocumab and placebo on any cognitive domain, even among patients whose LDL-C fell below 25 mg/dL [6]. That threshold is far below what inclisiran typically achieves in clinical practice, making the EBBINGHAUS reassurance directly applicable.

ODYSSEY OUTCOMES (Alirocumab) Psychiatric Signal

ODYSSEY OUTCOMES (N=18,924) followed post-acute coronary syndrome patients for a median 2.8 years on alirocumab or placebo. Prespecified analysis of neurocognitive adverse events found no significant difference between groups (1.5% alirocumab vs. 1.6% placebo) [7]. Depression and anxiety events were similarly balanced.

These datasets collectively suggest the drug class, not just inclisiran specifically, does not produce measurable psychiatric harm in controlled settings lasting up to three years.

Cholesterol, Serotonin, and Mood: The Biological Debate

What Cholesterol Does in the Brain

Roughly 25% of the body's total cholesterol resides in the central nervous system, despite the brain representing only about 2% of body weight. Neuronal cholesterol is synthesized locally; it does not depend substantially on circulating plasma LDL because the blood-brain barrier prevents LDL particle entry. That separation is the core reason why peripheral LDL reductions achieved by inclisiran are unlikely to affect brain cholesterol homeostasis [8].

Serotonin receptors are embedded in cholesterol-rich lipid rafts on neuronal membranes. In vitro studies have shown that membrane cholesterol content can influence 5-HT receptor conformation and sensitivity. However, these in vitro effects occur at cholesterol concentrations far removed from what plasma LDL reductions can achieve in neural tissue, and no in vivo human study has reproduced them at clinically relevant drug exposures [9].

The Steroid Hormone Pathway

Cholesterol is the biosynthetic precursor to all steroid hormones, including cortisol, testosterone, estradiol, and progesterone, all of which have documented effects on mood. A concern exists, in theory, that extreme LDL lowering could restrict substrate availability for adrenal or gonadal steroidogenesis. In practice, the adrenal gland and gonads synthesize steroid hormones primarily from locally stored cholesterol and HDL-derived cholesterol, not from circulating LDL. Statin trials have not demonstrated clinically significant reductions in circulating testosterone or cortisol even at LDL levels below 50 mg/dL, and inclisiran data are consistent with that pattern [10].

What Clinicians Should Tell Patients About Mood and Leqvio

A practical three-step framework for the clinical conversation:

Step 1. Acknowledge the question directly. Patients who ask about mood effects deserve a direct answer, not dismissal. The concern is biologically plausible in principle and worth addressing.

Step 2. Cite the actual trial data. In ORION-10 and ORION-11 (combined N=3,178, 18-month follow-up), psychiatric adverse event rates did not differ between inclisiran and placebo [4]. Patients with pre-existing depression or anxiety were not excluded from those trials, so the safety data include a real-world psychiatric population.

Step 3. Establish a monitoring plan. For patients with active depression, anxiety disorders, or a history of mood instability, a baseline PHQ-9 score before injection and a 3-month follow-up screen is a reasonable practice. This is not required by the FDA label, but it provides an objective measure that distinguishes nocebo responses from genuine drug effects.

Patients Who Should Receive Extra Monitoring

Certain groups warrant closer attention to mood during inclisiran therapy:

• Patients currently taking antidepressants, especially those with serotonin-related mechanisms, where any mood change could be ambiguous in origin.
• Patients with a history of major depressive disorder whose depression has been in remission for fewer than 12 months.
• Patients who express significant anxiety about the low-LDL itself, since nocebo effects from that belief can produce real subjective distress.

A PHQ-9 at baseline and at the month-3 injection visit costs nothing and creates a documented safety check. If scores worsen by 5 or more points in the absence of a life stressor, the prescriber should evaluate whether the change has another explanation before attributing it to inclisiran.

Nocebo Effects and Patient Expectations

The nocebo phenomenon, where negative expectations produce negative experiences, is clinically significant in lipid-lowering therapy. The SAMSON trial (N=60), published in the New England Journal of Medicine in 2020, found that 90% of statin-attributed muscle symptoms in a blinded challenge design were nocebo responses rather than pharmacological effects [11]. A similar pattern may apply to mood complaints if patients expect emotional side effects.

In clinical practice, the way a physician frames a medication's side effect profile shapes the rate of reported symptoms. Telling patients that inclisiran has not shown a psychiatric signal in controlled trials, while leaving the door open for them to report any change, strikes the right balance between informed consent and avoiding nocebo priming.

Long-Term Data Gaps and Ongoing Research

The longest inclisiran follow-up currently available comes from the ORION-3 open-label extension study, which followed patients for up to 4 years. The ORION-3 interim results, presented at the European Society of Cardiology 2022 congress, did not identify emerging psychiatric safety signals over that period, though formal publication with full adverse event tables was pending as of early 2025 [12].

What ORION-9 Adds for HeFH Patients

ORION-9 (N=482) enrolled patients with heterozygous familial hypercholesterolemia, a population that often begins lipid-lowering therapy in childhood or early adulthood and may have lifetime cumulative exposure to very low LDL levels. Psychiatric adverse event data from ORION-9 were similarly balanced between arms, with no signal distinguishing inclisiran from placebo [13].

The VICTORION-2 PREVENT Trial

The large cardiovascular outcomes trial VICTORION-2 PREVENT (target enrollment approximately 15,000 patients) is actively enrolling and will provide multi-year safety data including broader adverse event surveillance. That trial will be the most definitive source of information on rare or delayed psychiatric effects, if any exist [14].

FDA Label and Regulatory Perspective on Psychiatric Safety

The FDA prescribing information for inclisiran (approved December 22, 2021) does not include any psychiatric adverse reactions in the warnings and precautions section, nor are depression, anxiety, or cognitive impairment listed under adverse reactions [1]. The European Medicines Agency's assessment report for Leqvio similarly noted no meaningful imbalance in psychiatric events across the clinical trial program.

That regulatory judgment reflects a full review of the clinical trial adverse event database, not merely published summaries. The absence of a label warning after that level of scrutiny provides a degree of post-hoc reassurance beyond what individual trial publications can offer.

Practical Dosing Context and Why Twice-Yearly Scheduling Matters for Adherence

Inclisiran is administered at day 1, month 3, and then every 6 months by a healthcare provider in a clinical setting [1]. That scheduling eliminates the daily pill burden associated with statins. For patients whose mood difficulties are partly driven by medication fatigue or adherence anxiety, the twice-yearly model may represent an improvement in quality of life independent of any direct pharmacological effect on mood.

A patient who struggles to maintain daily statin adherence due to depression-related executive dysfunction may, paradoxically, achieve better LDL control on inclisiran simply because the injection schedule removes the need for daily decision-making. Improved cardiovascular risk management may itself benefit mood over the long term, given that ASCVD events are major precipitants of depression and anxiety [15].